Modality
Small Molecule
MOA
Anti-Aβ
Target
TROP-2
Pathway
Incretin
ALL
Development Pipeline
Preclinical
~Jan 2021
→ ~Apr 2022
Phase 1
Jul 2022
→ Feb 2031
Phase 1Current
NCT07378679
2,144 pts·ALL
2022-07→2029-12·Recruiting
NCT04749678
2,839 pts·ALL
2024-10→2031-02·Completed
4,983 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2029-12-073.7y awayInterim· ALL
2031-02-164.9y awayInterim· ALL
Trial Timeline
Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2
P1
Recruit…
P1
Complet…
Catalysts
Interim
2029-12-07 · 3.7y away
ALL
Interim
2031-02-16 · 4.9y away
ALL
RecruitingCompleted|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07378679 | Phase 1 | ALL | Recruiting | 2144 | SRI-4 |
| NCT04749678 | Phase 1 | ALL | Completed | 2839 | DAS28 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-8369 | Eli Lilly | Approved | Menin | |
| NVS-4076 | Novartis | Preclinical | TROP-2 | |
| NVS-8902 | Novartis | Preclinical | TROP-2 | |
| ABB-8696 | AbbVie | Phase 3 | BCMA | |
| Zanumavacamten | GSK | Phase 2/3 | TROP-2 | |
| BAY-6035 | Bayer | Phase 1 | C5 | |
| Zenotinib | BioNTech | Phase 1 | CGRP | |
| ION-1378 | Ionis | NDA/BLA | TROP-2 | |
| Nirafotisoran | Jazz Pharma | Phase 2/3 | TROP-2 | |
| ILM-4317 | Illumina | NDA/BLA | TROP-2 |